110 related articles for article (PubMed ID: 10812239)
1. Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin's lymphoma patients.
Singh RK; Varney ML; Ino K; Vose JM; Bierman PJ; Talmadge JE
Exp Hematol; 2000 May; 28(5):499-507. PubMed ID: 10812239
[TBL] [Abstract][Full Text] [Related]
2. Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.
Singh RK; Varney ML; Leutzinger C; Vose JM; Bierman PJ; Buyukberber S; Ino K; Loh K; Nichols C; Inwards D; Rifkin R; Talmadge JE
Int Immunopharmacol; 2007 Aug; 7(8):1033-43. PubMed ID: 17570320
[TBL] [Abstract][Full Text] [Related]
3. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
4. Reconstitution of naïve T cells and type 1 function after autologous peripheral stem cell transplantation: impact on the relapse of original cancer.
Mitra DK; Singh HP; Singh M; Alwadi A; Kochupillai V; Raina V; Kumar L; Mehra NK
Transplantation; 2002 Apr; 73(8):1336-9. PubMed ID: 11981431
[TBL] [Abstract][Full Text] [Related]
5. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
6. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells.
Tayebi H; Kuttler F; Saas P; Lienard A; Petracca B; Lapierre V; Ferrand C; Fest T; Cahn J; Blaise D; Kuentz M; Hervé P; Tiberghien P; Robinet E
Exp Hematol; 2001 Apr; 29(4):458-70. PubMed ID: 11301186
[TBL] [Abstract][Full Text] [Related]
7. Infusions of interleukin-1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity.
Katsanis E; Weisdorf DJ; Xu Z; Dancisak BB; Halet ML; Blazar BR
J Clin Immunol; 1994 May; 14(3):205-11. PubMed ID: 7929695
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
10. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow.
Talmadge JE; Reed E; Ino K; Kessinger A; Kuszynski C; Heimann D; Varney M; Jackson J; Vose JM; Bierman PJ
Bone Marrow Transplant; 1997 Jan; 19(2):161-72. PubMed ID: 9116614
[TBL] [Abstract][Full Text] [Related]
11. Changes in the T-helper cell 1/T-helper cell 2 balance of peripheral T-helper cells after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Mukai M; Bohgaki T; Kondo M; Notoya A; Kohno M
Ann Hematol; 2001 Dec; 80(12):715-21. PubMed ID: 11797111
[TBL] [Abstract][Full Text] [Related]
12. Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants.
Rutella S; Rumi C; Laurenti L; Pierelli L; Sora' F; Sica S; Leone G
Br J Haematol; 2000 Jan; 108(1):105-15. PubMed ID: 10651733
[TBL] [Abstract][Full Text] [Related]
13. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
14. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
[TBL] [Abstract][Full Text] [Related]
15. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
16. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma.
Haas R; Ehrhardt R; Witt B; Goldschmidt H; Hohaus S; Pförsich M; Ehrlich H; Färber L; Hunstein W
Bone Marrow Transplant; 1993 Dec; 12(6):643-9. PubMed ID: 7511017
[TBL] [Abstract][Full Text] [Related]
17. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution.
Guillaume T; Sekhavat M; Rubinstein DB; Hamdan O; Leblanc P; Symann ML
Cancer Res; 1994 Jul; 54(14):3800-7. PubMed ID: 7913409
[TBL] [Abstract][Full Text] [Related]
18. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
[TBL] [Abstract][Full Text] [Related]
19. Use of granulocyte colony-stimulating factor after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: what is the optimal timing?
Ener RA; Meglathery SB; Cuhaci B; Topolsky D; Styler MJ; Crilley P; Brodsky I; Kahn SB; King RS
Am J Clin Oncol; 2001 Feb; 24(1):19-25. PubMed ID: 11232944
[TBL] [Abstract][Full Text] [Related]
20. Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products.
Singh RK; Ino K; Varney ML; Heimann DG; Talmadge JE
Bone Marrow Transplant; 1999 Jan; 23(1):53-62. PubMed ID: 10037051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]